Invagen Pharmaceuticals Inc, a wholly owned subsidiary of Cipla announced that it has entered into a strategic partnership with Qilu Pharmaceutical Co. (Qilu), for the exclusive licensing and supply of QL2107, a biosimilar to Keytruda (pembrolizumab), for the United States.
Read more at the source
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.